Table 2.

Histochemical Evaluations Across Study Groups

Measurements	Control	DAPA	DOX	DOX + DAPA	P
	Mean ± SD (Median; Minimum–Maximum)
Inflammatory cell infiltration	0.17 ± 0.40a (0; 0-1)	0.17 ± 0.40b (0; 0-1)	2.67 ± 0.51a,b,c (3; 1-3)	0.50 ± 0.83c (0; 0-2)	.001*
Sarcomyolysis	0.00 ± 0.00a (0; 0-0)	0.17 ± 0.40b (0; 0-1)	2.83 ± 0.40a,b,c (3; 1-3)	0.33 ± 0.51c (0; 0-1)	<.001*
Necrotic changes	0.00 ± 0.00a (0; 0-0)	0.00 ± 0.00b (0; 0-0)	3.00 ± 0.00a,b,c (3; 3-3)	0.17 ± 0.40c (0; 0-1)	<.001*

Data are given as mean ± SD, number, or median (interquartile range).

DAPA, dapagliflozin; DOX, doxorubicin.

^a,b,cThe same superscript letters denote the significant pairwise comparison in each row according to Kruskal–Wallis critical difference post-hoc test.

*Significant at the .05 level according to two-way Repeated Measure ANOVA